Mindfulness Based Smoking Cessation Among Cancer Survivors

Summary

This study will examine the effect of a mindfulness-based smoking cessation program among cancer survivors.

Conditions

• Tobacco Smoking

Interventions

DRUG

Nicoderm C-Q Transdermal Product

6 weeks of nicotine replacement therapy patches

BEHAVIORAL

Orientation session

This session will occur 2 weeks before quit date. It will be moderated by a certified instructor in MT, and will last approximately 90 min. During the session, participants will learn the purpose, format, and procedures of the study, provide electronic informed consent which will be audio-recorded with their permission, and complete the baseline assessment.

BEHAVIORAL

Craving-to-Quit app

The app is comprised of 22 modules for 22 days, 5-15 minutes each, designed to teach MT using audio, video, and animation. The app also includes other features such as social support (quit friend sign-ups, the tip of the week), activity feed (to track interaction with the app), and my morning stats (to track smoking).

BEHAVIORAL

Two brief follow-up phone calls

The first phone call will occur one day before the quit date to remind participants about their quit date and provide support. The second will occur at the end of treatment (around day 60 after quit date) to review progress, provide support, and schedule the 3-month follow-up visit. Each phone call will last approximately 15 minutes.

BEHAVIORAL

Group MT sessions

Total of eight group sessions (twice a week) during 4 weeks. The overarching theme of momentary awareness and acceptance of cravings and affect (e.g., stress, anxiety etc.) will be introduced and reinforced in complementary ways throughout the training. Each session will last 45-60 minutes.

BEHAVIORAL

Brief advice on quitting smoking

Standard advice on how to quit smoking.

BEHAVIORAL

Self-help smoking cessation materials

Written materials on how to quit smoking including contact info for state tobacco quitline.

Sponsors & Collaborators

• University of Miami

  lead OTHER

Principal Investigators

• Taghrid Asfar, MD · University of Miami

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2019-09-28

Primary Completion

2024-05-19

Completion

2024-05-19

FDA Drug

Yes

Countries

• United States

Study Locations